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Leigh syndrome (LS) affects 1/40,000 newborn infants in the worldwide population and is characterized by the
presence of developmental delay and lactic acidosis and by a mean life expectancy variously estimated at 3–5 years.
Saguenay–Lac-Saint-Jean (SLSJ) cytochrome oxidase (COX) deficiency (LS French-Canadian type [LSFC] [MIM
220111]), an autosomal recessive form of congenital lactic acidosis, presents with developmental delay and hy-
potonia. It is an LS variant that is found in a geographically isolated region of Quebec and that occurs in 1/2,178
live births. Patients with LSFC show a phenotype similar to that of patients with LS, but the two groups differ in
clinical presentation. We studied DNA samples from 14 patients with LSFC and from their parents, representing
a total of 13 families. Because of founder effects in the SLSJ region, considerable linkage disequilibrium (LD) was
expected to surround the LSFC mutation. We therefore performed a genomewide screen for LD, using 290 autosomal
microsatellite markers. A single marker, D2S1356, located on 2p16, showed significant (P ! 1055) genomewide
LD. Using high-resolution genetic mapping with additional markers and four additional families with LSFC, we
were able to identify a common ancestral haplotype and to limit the critical region to ∼2 cM between D2S119 and
D2S2174. COX7AR, a gene encoding a COX7a-related protein, had previously been mapped to this region. We
determined the genomic structure and resequenced this gene in patients with LSFC and in controls but found no
functional mutations. Although the LSFC gene remains to be elucidated, the present study demonstrates the feasibility
of using a genomewide LD strategy to localize the critical region for a rare genetic disease in a founder population.
Introduction
The metabolic production of ATP is made possible by
electron transfer and proton pumping within the inner
membrane of the mitochondrion. This respiratory chain
consists of five major multiprotein complexes, of which
the cytochrome oxidase (COX) complex, known as
“complex IV,” catalyzes the crucial reaction of oxygen
reduction. COX is a multimeric, transmembrane protein
of ∼200 kD that consists of 13 subunits—of which 10
are encoded by nuclear DNA and 3 are encoded by
mtDNA. Inherited deficiencies of COX activity in hu-
mans have been reported to exist in multiple forms: au-
tosomal recessive, autosomal dominant, X linked, and
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maternal, and the variations are presumed to depend on
the gene involved (Dahl 1998). Only a few cases of COX
deficiency have been shown to result from defects in the
mitochondrial COX genes. Defects in three different nu-
clear genes that encode proteins involved in the matu-
ration and assembly of complex IV can also lead to COX
deficiencies. Each defect presents a different clinical phe-
notype: (1) mutations in SURF1 (Tiranti et al. 1998;
Zhu et al. 1998), a gene located in chromosomal region
9q34, have been associated with Leigh syndrome (LS
[MIM 256000]) (subacute necrotizing encephalomyop-
athy); (2) mutations in SCO2, a gene located in chro-
mosomal region 22q13 have been associated with fatal
infantile cardioencephalomyopathy (Papadopoulou et
al. 1999); (3) mutations in COX10, a gene located in
chromosomal region 17p13.1-q11.1, have been associ-
ated with tubulopathy and leukodystrophy (Valnot et al.
2000b); and (4) mutations in SCO1, a gene located in
chromosomal region 17p11, have been associated with
hepatic failure and encephalopathy (Valnot et al. 2000a).
In addition, although LS can result from mutations in
the SURF1 gene, it can also result from defects in py-
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ruvate dehydrogenase, mitochondrial complex I, mito-
chondrial complex V, or succinate dehydrogenase (Rob-
inson 1993; Bourgeron et al. 1995).
During the past few decades, several children in a
geographically isolated region of northeastern Quebec,
particularly in the Saguenay–Lac-Saint-Jean (SLSJ) re-
gion, were found to have a phenotype similar to that
of LS. Children with LS French-Canadian type (LSFC)
present with developmental delay and hypotonia
(Morin et al. 1993); because of acute crises of metabolic
acidosis and strokelike episodes, the death rate among
these infants is high (Merante et al. 1993; Morin et al.
1999). At autopsy, changes typical of LS are present;
and, although the course of LSFC is less fulminant than
that of most cases of LS described in the literature
(Montpetit et al. 1971; Pincus 1972), all the typical
features—including ataxia, dystonia, optic atrophy,
ophthalmoplegia, ptosis, nystagmus, tremor, and res-
piratory abnormalities—have been observed in various
patients with LSFC.
Many tissues from patients with LSFC are deficient
in COX activity. Specifically, brain and liver tissues have
10%–20% of the normal COX activity; fibroblasts and
skeletal muscle have 50%of normal activity; and kidney
and heart tissues have almost 100% of normal activity
(Merante et al. 1993). In humans, 2 (VIa and VIIa) of
the 10 nuclear-encoded subunits of COX exist in two
isoforms (heart and liver, denoted by “H” and “L,”
respectively), which differ both in sequence and in ex-
pression patterns. COXVIa-L and COXVIIa-L are ex-
pressed in many tissues, but COXVIa-H and COXVIIa-
H are expressed mainly in heart and skeletal muscle,
with low levels in smooth muscle. Because COX defi-
ciency is most pronounced in the liver of these patients,
liver tissue–mRNA samples were analyzed using north-
ern blot analysis for subunits VIa-L and VIIa-L (Mer-
ante et al. 1993). The transcript levels appeared to be
normal, but western blot analysis using an anti-holo-
enzyme COX antibody showed decreased amounts of
COX subunits within the liver mitochondria (Merante
et al. 1993). These results imply that, although the
mRNAs are present at normal levels, the COX subunits
fail to be efficiently assembled within the mitochondria,
at least in liver cells. However, sequencing of the 10
nuclear-encoded COX subunits (the liver isoforms of
VIa and VIIa) failed to identify any potential mutations
(Lee et al. 1998). Consequently, it is likely that the bi-
ochemical defect in patients with SLSJ COX deficiency
(i.e., LSFC) resides in a COX assembly factor or co-
factor that plays a more important role in the liver and
brain than in other tissues, such as kidney or heart.
The SLSJ region of Quebec is 125 miles northeast
of Quebec City and was settled during the years
1838–1911, during which ∼75% of the settlers were
from the Charlevoix region (Gavreau and Bourque
1988). The community of Charlevoix itself was started
in 1675, with 599 founders of French descent arriving,
in the course of seven generations, from Quebec City
(Jette et al. 1991; Labuda et al. 1996). There has been
little migration into the SLSJ region since 1870, and the
community has grown from 18,000 in 1852 to 320,000
in 2000 (Labuda et al. 1996). Because of the founder
effect (De Braekeleer et al. 1993; Heyer 1999), several
dominant and recessive genetic disorders are more prev-
alent in the SLSJ region than they are elsewhere. The
incidence of LSFC is 1/2,178 live births (De Braekeleer
et al. 1993), and carrier rates for LSFC have been es-
timated to be 1/23 adults (Morin et al. 1993). Several
other autosomal recessive disorders that also have a
prevalence of ∼1/2,000 include cystic fibrosis, tyrosi-
nemia type I, vitamin D–dependent rickets, polyneu-
ropathy with corpus callosum agenesis, and autosomal
spastic ataxia of Charlevoix-Saguenay (De Braekeleer
et al. 1991).
Founder effects are reflected in the limited allelic di-
versity observed in patients with these diseases. For ex-
ample, De Braekeleer et al. (1998) recently demon-
strated, after complete ascertainment, that only three
mutations account for 94% of all cystic fibrosis chro-
mosomes in this population. Even more striking is the
observation that a single homozygous mutation was
found in 80% of patients with the hereditary tyrosi-
nemia type I in the SLSJ region (Grompe et al. 1994).
Moreover, because of the founder effect in a young pop-
ulation, large blocks of ancestral DNA have been shown
to flank the disease mutations in this population. Spe-
cifically, recent studies have demonstrated that ancestral
haplotypes spanning ∼8–10 cM are common to 40%–
60% of affected chromosomes (4–6 cM being common
to nearly 80%) of populations with rare diseases from
this region (Labuda et al. 1996; Richter et al. 1999;
Couture et al. 1999).
Because the mean life expectancy for individuals with
LSFC is 3–5 years (range 0–7 years), the majority of
families with LSFC have only one affected child and no
other affected immediate relatives. Consequently, al-
though we had almost complete ascertainment of pa-
tients with LSFC during a period of 7 years, DNA sam-
ples from only 14 affected children from 13 families
were available for study; the lack of multiplex families
prevented a traditional linkage approach to disease-gene
discovery. Because of the population characteristics of
the SLSJ region, a genomewide LD search was per-
formed to identify the LSFC gene. Using analysis of the
genotype data from a total of 312 autosomal micro-
satellite markers, we identified a single marker, located
on chromosome 2p16, that was in LD with the LSFC
phenotype. High-resolution mapping with 11 addi-
tional microsatellite markers limited the critical region
to ∼2 cM, between D2S119 and D2S2174.
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Families, Material, and Methods
Families and DNA Isolation
Patients were diagnosed with LSFC on the basis of
phenotype, genetic epidemiology, lactic acidemia, pa-
thology, and levels of COX activity (Morin et al. 1993).
DNA samples were drawn from children with LSFC and
from their parents, after the parents had given informed
consent. The probands were ascertained among patients
who came to the attention of C.C.M. or G.A.M. during
the period 1990–97. The DNA samples were extracted
from blood, frozen tissue, fibroblast cell cultures, or fro-
zen lymphoblast cell lines. Some individuals with LSFC
were not included in the genetic study, because their
samples were not available or did not yield sufficient
DNA.
The genetic material available for the genomewide
screen came from 14 patients with LSFC and from 26
parents, representing 13 families (family COX007 had
two affected siblings). For the high-resolution mapping,
DNA samples were collected from four additional fam-
ilies with LSFC and were genotyped. In one of these
pedigrees (COX014), DNA samples from both parents
and one affected child were available; in two pedigrees
(COX005 and COX006), DNA was available from only
one parent and one affected child; and in one pedigree
(COX022-58), only the affected child’s DNA was avail-
able. Control DNA samples were collected from indi-
viduals in the SLSJ region who were not affected by
LSFC and who had no children with LSFC.
Genomewide Screen and High-Resolution Mapping
The genomewide screen was performed using the
DNA samples from the initial group of 13 families with
LSFC; the screen was performed using 290 fluorescence-
labeled microsatellite markers, which had an average
intermarker distance of 12 cM. The markers were from
a modified version of the Cooperative Human Linkage
Center (CHLC) human screening set (Research Genet-
ics). The reactions were set up with a robotic pipetting
station (Rosys Robotic Systems) in 192-well polypro-
pylene plates (Corning Costar) and were subjected to
PCR conditions in a customized thermocycler (Intelli-
gent Automation Systems). PCR products were pooled
into panels (8–10 markers per panel) on the basis of
allele size range and fluorescence labeling. Aliquots of
these samples were mixed either with Tamra-labeled
GENESCAN 500 and GENESCAN 2500 (Applied Bio-
systems) or with rhodamine-labeled MapMarkers (Bio-
ventures), and sequencing was performed on ABI 377
sequencers (Applied Biosystems). Gels were processed,
tracked, and reviewed using an automated system de-
veloped at the Whitehead Institute for Biomedical Re-
search/MIT Center for Genome Research, as described
elsewhere (Rioux et al. 1998). Allele binning and in-
heritance checking were performed with PEDMANA-
GER (developed by M. P. Reeve-Daly and M. J. Daly).
The high-resolution mapping of the chromosome 2p16
region was performed using 11 additional markers flank-
ing marker D2S1356 and in DNA samples from 18 in-
dividuals with LSFC and from 30 of their parents. The
additional markers used for the scan were selected from
the Ge´ne´thon sex-averaged genetic map of chromosome
2. They were GATA194B06, D2S2305, D2S2259,
D2S2306, D2S2294, D2S119, D2S2298, D2S2174,
D2S2291, D2S2240, and D2S2378. The original
marker, D2S1356, was also regenotyped to confirm the
results from the genomewide screen. Samples for PCR
were set up in 96-well polypropylene plates (MJ Re-
search) and were amplified in a thermocycler (MJ Re-
search). The gels were electrophoresed and processed in
a manner similar to that used for gels in the genomewide
screen.
Statistical Analysis
The genotype data from the genomewide screen were
analyzed using the transmission/disequilibrium test
(TDT). Specifically, the alleles at each of the 290markers
were examined for excess transmission from heterozy-
gous parents to children with LSFC. To assess the sig-
nificance of the genomewide TDT results for marker
D2S1356, permutation tests were performed using the
same genotype data. For each trio, chromosomes were
randomly reassigned as transmitted or untransmitted, to
form a permuted data set. The percentage of permuted
data sets with values as significant as that seen at
D2S1356 was calculated.
Four additional families with LSFC were genotyped
for marker D2S1356, but both parental genotypes were
available for only one of these. Fisher’s exact test was
used to determine the significance of the difference be-
tween non-238 alleles and 238 alleles, in the LSFC and
control chromosomes from the same population. The
control genotype data for marker D2S1356 were derived
from unrelated individuals (without LSFC) who were
patients at the Hoˆpital de la Sagamie, in the SLSJ region.
To quantify the extent of LD in the region surrounding
marker D2S1356, Pexcess (d) was computed for the
genotype data from the markers included in the high-
resolution mapping. Pexcess represents the strength of LD
and is calculated according to the following formula:
. In our study, the Paffected(P  P )/(1 P )affected normal normal
value is calculated from the frequency of the common
allele in all the patients with LSFC, and the Pnormal value
is the frequency among untransmitted parental chrom-
osomes.
400 Am. J. Hum. Genet. 68:397–409, 2001
Screening YAC Clones from the 2p16 Region
In an attempt to determine whether the previously
known subunits of COX could be mapped to the region
identified by use of the genome scan, we designed pri-
mers for the COX subunits and screened them with a
collection of YAC clones previously mapped to 2p16
(Whitehead Institute for Biomedical Research). The
primers designed from the 3′UTR of each cDNA se-
quence by Primer software, version 3.0 (Whitehead In-
stitute for Biomedical Research), were specific to the 10
COX subunits (IV, Va, Vb, VIa-L, VIb, VIc, VIIa-L, VIIb,
VIIc, and VIII) and three of its assembly factors
(COX10, COX17, and OXA1).
The sequences for the forward and reverse primers are
as follows: COXIV, 5′-aacgagtggaagaagtgaga-3′ and
5-gtaaataggcatggagttgc-3′; COXVa, 5′-cccaaggattta-
ttgacatt-3′ and 5′-ccattacatggcttggtact-3′; COXVb, 5′-
actgagcacctgcactaaat-3′ and 5′-gagaaggagccaatgcaa-3′;
COXVIa, 5′-gggaccttaagctaaccttc-3′ and 5′-ttatttaagcca-
tctcctgc-3′; COXVIb, 5′-catctccctttcctctgtc-3′ and 5′-cat-
gatttaggatcctggg-3′; COXVIc, 5′-ggctggtatctttcagagtg-3′
and 5′-ttcaggaacacaagtcagtg-3′; COXVIIa, 5′-ggttcagtt-
tcattcagctc-3′ and 5′-gctttattggtggcagttac-3′; COXVIIb,
5′-aaaggaatggaggaatcagt-3′ and 5′-acagtgctttaatttggcat-
3′; COXVIIc, 5′-aaggatgtttcagttcctcc-3′ and 5′-ttctagttt-
gatccacttcca-3′; COXVIII, 5′-ggatcatgtctattcaattcc-3′ and
5′-tttattgttacaagggggac-3′; COX10, 5′cttgacaggatgttttc-
gat-3′ and 5′-tgcaatgttctccacagtaa-3′; OXA1, 5′-agcctt-
caaccttctagctg-3′ and 5′-aaggaaaagtgcaaatgtgg-3′; and
COX17, 5′-tccacatatcaaagttcgtcaaag-3′ and 5′-aggaga-
agaagccgctgaa-3′.
Each primer pair was tested on each of the following
YAC clones, covering a region of ∼10–15 Mb around
D2S1356: 929d9, 718e9, 872c7, 816c8, 908h7, 798f2,
849e9, 934e2, 748b9, 933b10, 930a1, 957b10, 913g4,
761e1, 972c5, 919c10, 955f10, 945f10, 945g11, 944d7,
899f9, 819a6, and 797a3. The PCR reactions were set
up in 96-well polypropylene plates and were amplified
in thermocyclers (MJ Research). The products of these
reactions were electrophoresed on 1% agarose gels, and
the presence or absence of bands of expected size indi-
cated whether these genes were located within the ge-
nomic region represented by the overlapping YAC
clones.
Genomic Structure of COX7AR
After determination of the LSFC critical region, by
use of the genomewide and high-resolution mapping, a
search through the Genemap database (National Center
for Biotechnology Information) identified a cDNA se-
quence for a possible candidate gene called “COX7AR,”
which mapped close to marker D2S119. To screen the
patients’ DNA for mutations, the genomic sequence for
this candidate gene was elucidated. Specifically, several
PCR primer pairs were designed using the published
COX7AR cDNA sequence (GenBank accession number
AB007618). One pair of primers was 5′-gatgcgggaagc-
cggactct-3′ and 5′-ccagtcctctgcagcgtaag-3′, which cover
the coding region and give an expected size of 392 bp
on cDNA. Another pair was 5′-catgtactacaagtttagtgg-3′
and 5′-aaaaggaccttcaaaagggttt-3′, which also span the
coding region and which amplify 404 bp on cDNA. A
third set of primers was 5′-atctcctatctttagtgaaatct-3′ and
5′-tcatgtatttattccacagtc-3′, which span a 198-bp region
in the 3′UTR. PCR assays using these primer pairs were
then performed to screen pooled P1 artificial chromo-
some (PAC) clones.
The DNA for three positive PAC clones (RPCI-
5.1126_I_4, RPCI-5.1148_J_17, and RPCI-5.1149_D
_18) were isolated and used as templates in sequencing
reactions. The cDNA-specific primers were used for di-
rect sequencing of the PAC DNA, with the BigDye Ter-
minator sequencing kit (Applied Biosystems). The se-
quencing reactions were purified with Sephadex G-50
medium-grade chromatography columns (Pharmacia).
The samples were then electrophoresed on ABI 377 se-
quencers (Applied Biosystems). The sequencing gel files
were processed with Bass/Grace software (Whitehead In-
stitute for Biomedical Research), and base calling was
performed using the TROUT software program (White-
head Institute for Biomedical Research). The sequences
were aligned using the Staden software package (Staden
1996). The entire intronic sequence, together with ∼1
kb of the 5′UTR and 315 bp of the 3′ end of the 3′UTR,
was determined for this gene by an iterative approach
of direct sequencing with primers designed from the
newly obtained sequence. This genomic sequence was
examined for potential transcription factor–binding
sites, by TFSEARCH (version 3.1), with a threshold of
85.0 points.
Mutation Screening and Physical Mapping of COX7AR
To screen for potential mutations in the DNA of pa-
tients with LSFC, overlapping PCR assays were designed
to amplify the DNA samples from three to five patients
with LSFC and from three control individuals. Each PCR
product was purified using the solid-phase reversible im-
mobilization technique (Hawkins 1994), and then both
strands were sequenced using the ThermoSequenase
DYEnamic direct cycle-sequencing kit (Amersham). The
products from the sequencing reactions were electro-
phoresed on ABI 377 DNA sequencing machines and
were processed as described above. Three of the four
single-nucleotide polymorphisms (SNPs) discovered
through the use of this methodology were then geno-
typed in DNA samples from the remaining patients with
LSFC and from their parents, by resequencing of both
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Table 1
Results of the TDT for D2S1356
NO.
ALLELE Transmitted Untransmitted x2 P
232 0 3 3 .083
235 0 8 8 .005
238 21 1 18.18 .00002
240 0 1 1 .317
244 0 3 3 .083
247 1 2 .33 .564
250 0 3 3 .083
253 0 1 1 .317
Table 2
Results of Test of Association for D2S1356 among
the Population with LSFC and among the
Saguenay Control Population
NO. OF ALLELES (FREQUENCY) IN
ALLELE
SIZE
Population
with LSFC
Control
Population
223 0 (0) 1 (.04)
232 0 (0) 7 (.029)
235 1 (.028) 51 (.208)
238 34 (.944) 82 (.335)
241 0 (0) 8 (.033)
244 0 (0) 33 (.135)
247 1 (.028) 14 (.057)
250 0 (0) 38 (.155)
253 0 (0) 10 (.041)
257 0 (0) 1 (.004)
strands. Each sequence trace was independently re-
viewed by at least two individuals.
Immunoblotting of COX7RP
Mitochondria were isolated, as described elsewhere,
from cultured skin fibroblasts of patients with COX de-
ficiency (Pitka¨nen and Robinson 1996). Antibodies
against COX7RP were generated by injecting rabbits
with a peptide identical to the last 12 amino acids of
the protein conjugated to keyhole limpet hemocyanin
(Research Genetics). Mitochondrial proteins (100 mg of
protein) were separated on 18% SDS-PAGE gels and
transferred to a 0.2-mm nitrocellulose membrane. Im-
munoblotting procedures were performed, as described
by McEachern et al. (2000), using a 1:2,000 dilution of
primary antibody for all three antibodies. Antibody to
beef heart COX was generated as described by Merante
et al. (1993). SURF1p antibodies were generated by in-
jecting rabbits with a SURF1/glutathione transferase–
fusion protein generated in bacteria.
Results
Genomewide Screen and High-Resolution Genetic
Mapping
Because the expected LD surrounding the LSFC mu-
tation was ∼8–10 Mb, a genomewide search for LD was
undertaken with 290 evenly spaced microsatellite mark-
ers. Specifically, DNA samples from 13 families, com-
prising 14 children with LSFC (one affected sibling pair
and 12 singletons) and 26 parents, were genotyped for
all markers. By use of the TDT, the alleles at each marker
were examined for excess transmission. From the entire
genome scan, only one marker—D2S1356, located in
chromosomal region 2p16—showed significant LD with
the LSFC phenotype. Table 1 shows the results from the
TDT for marker D2S1356 and demonstrates that allele
238 is in strong disequilibrium with the LSFC chro-
mosomes. Although the observed excess transmission
was associated with a significant P value (1.2 # 105),
we had tested close to 300 microsatellite markers and
needed to estimate the significance of this finding after
correction for multiple hypothesis testing. A conserva-
tive Bonferroni correction for performing 1,500 tests
(300 markers, each with five alleles) would suggest a
corrected P value of ∼.02. To determine a more accurate
estimate of significance, we also performed permutation
tests with the same genotype data but with the trans-
mitted/untransmitted status assigned at random. Of 1
million permutations of our entire genomewide screen,
only 2,051 (0.2%) contained a result as strong (P !
) as the result observed for D2S1356, which in-.0001
dicated that the LD for this marker was of genomewide
significance.
DNA samples from four additional probands with
LSFC and from their parents were then genotyped for
the D2S1356 marker. Because DNA samples were avail-
able for both parents in only one of these additional
families, the full data set was examined for association,
by use of a case-control design. Because the TDT results
indicated that allele 238 was associated with the disease,
Fisher’s exact test was used to compare the proportions
of all non-238 and 238 alleles in the case population (2
and 34, respectively) and in the control population (163
and 82, respectively). The results from this test dem-
onstrated a highly significant ( ) association be-12P ! 10
tween allele 238 of marker D2S1356 and the LSFC phe-
notype (table 2).
After using LD to map the LSFC gene to a chromo-
somal region surrounding marker D2S1356, we geno-
typed 11 additional microsatellite markers in the 18
LSFC samples, to identify the ancestral haplotype and
to delimit the LSFC critical region. An ancestral LSFC
haplotype was defined by the allele, at each marker, that
was most common to the LSFC chromosomes and that
showed the highest Pexcess value. Specifically, GATA-
194B06, D2S2305, D2S2259, D2S2306, D2S1356,
D2S2294, D2S119, D2S2298, D2S2174, D2S2291,
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Table 3
Genotypes of 36 LSFC Chromosomes in the 2p16 Region
COX7AR SNP
MAP OR PROBAND GATA194B06 D2S2305 D2S2259 D2S2306 1 2 4 D2S1356 D2S2294 D2S119 D2S2298 D2S2174 D2S2291 D2S2240 D2S2378
Genetic Distance
(cM)
Genetic Distance
(cM)
Map:
Marshfield 61.66 61.66 63.41 64.29 64.84 65.39 65.94 67.58 69.77 69.77 70.31
Ge´ne´thon 66 67.4 67.4 67.5 68.2 69 69.5 71.4 73.3 73.3 73.8
Allele Size Allele Size
Proband:
COX001-1 288 124 241 207 A G nd 238 234 223 225 278 240 186 198
288 124 245 207 A G nd 238 234 223 225 278 240 186 198
COX003-5 284 124 245 207 A G G 238 234 223 225 278 236 184 198
288 124 245 207 A G G 238 234 223 225 278 240 186 198
COX004-8 288 124 245 207 A G G 238 234 223 225 278 240 178 198
288 124 245 207 A G G 238 234 223 225 278 240 188 200
COX005-9 260 132 245 207 A G G 238 234 223 225 278 240 186 198
288 124 245 207 A G G 238 234 223 225 278 240 186 198
COX006-10 284 124 245 207 A G G 238 234 223 225 278 nd 186 198
288 124 245 207 A G G 238 234 223 225 278 nd 186 198
COX007-12 280 128 229 197 nd A A 247 230 223 225 276 236 184 204
288 124 245 207 nd G G 238 234 223 225 278 240 178 200
COX007-13 288 124 245 207 A G G 238 234 223 225 280 240 186 200
403
288 124 245 207 A G G 238 234 223 225 278 242 178 200
COX008-16 nd nd nd 207 A G G 238 234 223 225 278 240 nd 198
nd nd nd 207 A G G 238 234 223 225 278 240 nd 198
COX009-19 288 124 245 207 A G G 238 234 223 225 278 240 186 198
288 124 245 207 A G G 238 234 223 225 278 240 186 198
COX011-25 260 128 245 207 A G nd 238 234 223 225 278 240 186 198
260 132 245 207 A G nd 238 234 223 225 278 240 186 198
COX012-27 288 124 245 207 A G G 238 234 223 225 278 240 186 198
288 124 245 207 A G G 238 234 223 225 278 236 174 200
COX013-29 260 132 245 207 A G G 238 234 223 225 278 240 186 198
288 124 245 207 A G G 238 234 223 225 278 240 178 200
COX014-32 288 124 245 207 nd nd nd 238 234 223 225 278 nd 186 198
288 124 245 207 nd nd nd 238 234 223 225 278 nd 186 204
COX016-38 260 132 245 207 A G G 238 234 223 225 278 236 186 214
288 124 245 207 A G G 238 234 223 225 278 242 174 204
COX018-43 264 132 231 197 T A A 238 234 223 221 278 240 186 192
260 124 245 207 A G G 238 234 223 225 278 240 186 214
COX020-55 288 124 241 207 A G nd 238 234 223 225 278 240 186 198
288 124 245 207 A G nd 238 234 223 225 278 240 186 198
COX021-57 263 130 227 201 A A A 235 226 225 225 278 240 182 204
291 124 245 207 A G G 238 234 223 225 278 236 186 198
COX022-58 264 130 nd 197 A A A 238 234 223 225 278 240 184 198
288 124 nd 207 A G G 238 234 223 225 278 240 186 198
NOTE.—Boxes denote alleles not shared by the LSFC ancestral haplotype; nd p no data.
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Figure 1 Haplotypes of patients with LSFC, for the microsatellite markers that gave significant Pexcess values. A, Ancestral haplotype, as
defined by the markers (shared by 26 [72%] of 36 individuals). B, Pexcess values for all the markers, with their Ge´ne´thon map distances.
D2S2240, and D2S2378 (spanning ∼10 cM) defined the
following ancestral haplotype: 288-124-245-207-238-
223-225-278-240-186-198 bp (table 3). In addition,
185% (31/36) of the LSFC chromosomes were identical
over a 4-cM region defined by markers D2S2306,
D2S1356, D2S2294, D2S119, D2S2298, and D2S2174.
This overlaps with the region of peak disequilibrium
defined as (fig. 1). Further examination of theP 1 .8excess
LSFC chromosomes reveals that, apart from a likely mu-
tation in individual COX018-43, the only marker show-
ing identity across all LSFC chromosomes is D2S2298
(table 3). Specifically, this LSFC critical region is defined
by the affected chromosomes (bearing the 225 bp allele
at D252298) from families COX007 and COX021 (ta-
ble 3), and figure 2 depicts the recombination event that
is likely to have occurred in the maternal chromosome
of family COX007, between markers D2S2294 and
D2S119 or between D2S119 and D2S2298. Taken to-
gether, these results indicate that the LSFC critical region
is ∼2 cM between D2S119 and D2S2174.
Candidate Genes within the LSFC Critical Region
The genomic locations of several genes that encode
the COX subunits and assembly factors were unknown,
and we were interested in determining whether any were
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Figure 2 Pedigree and haplotypes of members of family
COX007, for some of the markers used in the high-density mapping
of LSFC. The inherited paternal chromosome is framed in the right
column, for father and both daughters. Straight lines indicate the ma-
ternal chromosomes, and the points of recombination are depicted in
the maternal genotype. The thicker vertical lines indicate the maternal
alleles inherited by patient 7-12, and the thinner vertical lines indicate
the maternal alleles inherited by patient 7-13. The two patients share
alleles only for D2S119 and D2S2298.
located within the LSFC critical region. None of the 10
COX subunits (IV, Va, Vb, VIa-L, VIb, VIc, VIIa-L, VIIb,
VIIc, or VIII) and none of the three assembly factors
(COX10, COX17, or OXA1) mapped to any of the 23
MEGAYAC clones that cover this region (data not
shown). In contrast, a search of the National Center for
Biotechnology Information (NCBI) public databases for
genes located in the 2p16 region identified a cDNA se-
quence that was predicted to encode a protein similar
to COXVIIa. The protein is known as “COX7-related
protein” (COX7RP [GenBank accession number
AB007618]), and its corresponding gene is named
“COX7AR.” COX7AR had been mapped using radi-
ation hybrids with two different markers, stSG3793 and
A007B18, on GeneMap ’98 (NCBI). Marker stSG3793
mapped to an interval between markers D2S119 and
D2S337, and A007B18 mapped to between D2S177 and
D2S119. Although the function of COX7RP is un-
known, COX7AR appeared to be a possible candidate
gene for LSFC, because its C-terminal region has a high
amino acid–sequence identity with both liver and heart
isoforms of COXVIIa and is well conserved between
humans and mice (Watanabe et al. 1998).
Genomic Structure of COX7AR
To screen patients’ DNA samples for an LSFC mu-
tation, the genomic structure of COX7AR was deter-
mined. This was accomplished by isolation of large insert
genomic DNA clones containing COX7AR and by use
of these as templates in sequencing experiments. Three
PAC1 clones (1126_I_4, 1148_J_17, and 1149_D_18)
were isolated. The sequencing experiments revealed that
COX7AR consists of three exons—of 111, 132, and 817
bases—that are separated by introns of 3,753 and 1,898
bases (fig. 3). Exon 1 contains a 5′UTR of 39 bases, and
exon 3 contains a 3′UTR of 723 bases. Examination of
slightly more than 1 kb of sequence upstream from the
start codon revealed consensus CCAT boxes at nucle-
otide positions 127 and 397, as well as several po-
tential binding sites for Sp1, Oct-1, HNF-3b, and NF-
kB transcription factors.
Mutation Screening and Physical Mapping of COX7AR
Overlapping PCR assays, spanning nearly 8 kb of ge-
nomic sequence, were designed for resequencing of
COX7AR in DNA samples from five patients with LSFC
and from three control individuals. Resequencing of
both strands of DNA in these samples revealed four
nucleotide positions where the sequence differed be-
tween patients and controls. The four SNPs were located
at positions516, 145, 1331, and 4277 and are referred
to here as “SNP1,” “SNP2,” “SNP3,” and “SNP4,” re-
spectively (fig. 3). Three of the four SNPs (1, 2, and 4)
were examined by resequencing in the remaining DNA
samples from patients with LSFC (table 3) and from their
parents (data not shown). None of these SNPs appear
likely to be the disease-causing mutation, because none
are predicted to change the function or expression of
COX7RP; they do not change predicted amino acid se-
quence and are not located wihin the intron/exon bound-
aries or cis-acting elements. In addition, two individuals
with LSFC (COX007-12 and COX018-43) are hetero-
zygous for these SNPs, and 10 of the parents were ho-
mozygous for the ancestral haplotype defined by these
SNPs. Moreover, these SNPs are not part of the con-
served haplotype, a finding that placesCOX7AR outside
the LSFC critical region and that probably excludes the
possibility that the LSFC mutation is actually within
COX7AR but remains undetected.
Immunoblotting of mitochondrial proteins, using an
antibody generated against COX7RP, showed that levels
of expression in control subjects were similar to those
(1) in patients with COX deficiency due to mutations in
SURF1, (2) patients with COX deficiency and LS of
unknown origin, and (3) three patients with LSFC (fig.
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Figure 4 Immunoblotting of mitochondria from fibroblast cul-
tures. Mitochondria (100 mg) were prepared from skin fibroblast cul-
tures, were subjected to PAGE separation, and were transferred to
nitrocellulose. Parallel prepared blots were then probed with antibod-
ies to beef heart COX (top), SURF1 (middle), and COX7RP (7aRP)
(bottom). The anti-COX antibody recognizes subunits II, IV, Vb, and
VIa of the human COX complex. Lane 1, Control. Lanes 2, 3, and
5, Patients with LS and SURF1 mutation. Lane 4, Patients with LS
COX deficiency and normal SURF1. Lanes 6, 7, and 8, Patients with
LSFC-COX.
Figure 3 Genomic structure of COX7AR. The genomic sequence was determined for a region of 7934 bp. This region contained the
entire COX7AR gene, consisting of three exons (of 111, 132, and 817 bp, respectively), two introns (of 3753 and 1898 bp, respectively), and
the 5′ upstream region of 1007 bp. The four SNPs found in the SLSJ population are referred to here as SNP1, SNP2, SNP3, and SNP4.
4). Parallel blotting analysis done with anti-SURF1
antibody and anti-COX antibody shows low expression
of COX subunits in several patients and low expression
of SURF1 in patients with SURF1 mutations.
Discussion
Isolated COX deficiencies represent a common cause of
mitochondrial respiratory-chain defects in humans.Only
a few rare cases of mutations in the mitochondrial-en-
coded subunits have been identified. In contrast, three
genes that encode proteins involved in the assembly of
the COX subunits have recently been shown to be mu-
tated in patients with various COX deficiencies. Specif-
ically, these are the SURF1, SCO2, and COX10 genes,
located in chromosomal regions 9q34, 22q13, and
17p13.1-q11.1, respectively (Tiranti et al. 1998; Zhu et
al. 1998; Papadopoulou et al. 1999; Valnot et al. 2000a).
Less than a decade ago, a distinct autosomal recessive
COX deficiency was characterized that was specific to
the SLSJ region of Quebec (Merante et al. 1993; Morin
et al. 1993). In an effort to identify the gene defect that
causes this deficiency, samples were collected from fam-
ilies with LSFC. Given the devastating effect of COX
deficiency on a child’s life expectancy, we were able to
collect samples only from families that had one affected
child and from a single family that had an affected sib-
ling pair. This limitation made a linkage study impos-
sible. The known characteristics of the SLSJ population,
however, made it likely that LSFC was caused by a single
major mutation present on a common haplotype ex-
tending over a distance of many centimorgans.We there-
fore undertook a genomewide screen for LD and suc-
cessfully identified an allele of a single marker (allele
238 of marker D2S1356), on chromosomal 2p16, that
was in significant disequilibrium with the LSFC phe-
notype. Although the identity of the LSFC gene has yet
to be determined, its chromosomal position clearly in-
dicates that it is distinct from the genes involved in the
previously described COX deficiencies.
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Moreover, because none of the 10 nuclear-encoded
COX subunits map to this region, it is very likely that
the LSFC gene product is involved in COX assembly,
as has been observed for the other nuclear-encoded
COX deficiencies (Tiranti et al. 1998; Zhu et al. 1998;
Papadopoulou et al. 1999; Valnot et al. 2000a, 2000b).
Specifically, SCO1 and SCO2 are involved with copper
transfer, COX10 is the gene for heme farnesyl trans-
ferase, and SURF1 has been shown to be involved with
the subunit-assembly process. To date, ∼40 genes are
associated with COX assembly in the yeast Saccharo-
myces cerevisiae model (Glerum 1999), and 10 have
been identified—and have been recently mapped—in
humans. Some of the potential processes of the LSFC
gene are as follows: subunit synthesis, assembly, and
degradation; chaperone roles; heme transport and syn-
thesis; transport and placement of the metals copper,
zinc, magnesium and iron. It may also reduce activities
in COX by affecting the binding to either cytochrome
c or oxygen or by affecting electron transfer or stability.
Somewhat different from what is seen in the other COX
deficiencies, however, is the fact that LSFC-COX dis-
plays some tissue specificity. The gene responsible for
LSFC-COX is likely to be an assembly factor that affects
the enzyme in the liver and brain tissues more than in
the heart or kidney.
High-resolution genetic mapping, using 11 additional
markers that spanned ∼10 cM in the region surrounding
marker D2S1356, identified a haplotype likely to rep-
resent the chromosome of a common founder. More
specifically, a single haplotype defined by markers
D2S2306, D2S1356, D2S2294, D2S119, D2S2298, and
D2S2174 (alleles 207, 238, 234, 223, 225, and 278,
respectively), extending over a region of ∼4 cM, is pre-
sent in 180% of LSFC chromosomes and almost cer-
tainly contains the LSFC gene. Such a large extent of
disequilibrium surrounding the disease locus was ex-
pected in view of the unequal contribution, ∼12–15 gen-
erations ago, of a small number of founders of this
population (Heyer 1995). Additionally, this finding was
supported by experimental results from previous studies
of rare diseases within the SLSJ region (Labuda et al.
1996; Richter et al. 1999). On examination of family
COX007, the identification of a maternal recombina-
tion event narrowed the LSFC critical region to the ∼3-
cM interval between markers D2S2294 and D2S2174.
In addition, the observation that the individual with
LSFC from family 21 (COX21-57) is homozygous only
for markers D2S2298 and D2S2174 further reduces the
critical region, to the ∼2-cM interval between D2S119
and D2S174. Patient COX18-43 is heterozygous at
marker D2S2298; however, because of the extensive
match with the ancestral haplotype for ∼1.5 cM on
either side of D2S2298, we believe that the heterozy-
gosity in this patient is most likely the result of a mu-
tational event at the marker (Brinkmann et al. 1998).
No known COX subunits or assembly factors
mapped to the region identified by the LD and high-
resolution mapping. After we performed these experi-
ments, other research groups mapped COX subunits
and more assembly factors: SCO1, COX11, COX15,
paraplegin, and pet112-L, on chromosomal regions
17p12-13, 17q22, 10q24, 10p14, and 4q27-q28, re-
spectively (Casari et al. 1998; Petruzzella et al. 1998).
In agreement with the results of our screening, none of
the subunits map to 2p16. A search of the NCBI public
databases identified a potential candidate gene called
“COX7AR.” This gene had been mapped, by use of
radiation hybrids, to an interval that overlapped the
LSFC region. Its gene product was called “COX7A-
related protein,” because it had extensive amino
acid–sequence identity with the two isoforms of the
mammalian COXVIIa family (Watanabe et al. 1998).
Although the biochemical role of COX7RP has yet to
be determined, its mouse orthologue (called “SIG81”)
was shown to localize to the mitochondria (Segade et
al. 1996). Determination of the genomic structure of
the COX7AR gene made it possible to screen the pa-
tients’ DNA for potential mutations. Given that all the
sequence differences between patients and controls were
located within COX7AR introns, none were likely to
be the LSFC mutation. Furthermore, genotyping of
these SNPs in samples from all the patients and parents
indicated that this gene must be located outside the crit-
ical region, clearly demonstrating that the LSFC gene
has yet to be identified. Finally, immunoblots using mi-
tochondria from both patients with COX deficiency due
to SURF1 mutations and from patients with SLSJ-COX
deficiency showed normal levels of COX7ARp while
clearly showing decreases of COX subunits, indicative
of poor assembly of the mature COX complex. This
result, along with the normal exon sequence of the
7ARP gene, strongly suggests that this gene is not con-
nected with SLSJ-COX deficiency. At the time this ar-
ticle was submitted for publication, no human genome
sequence covering the markers D2S119 and D2S2298
had been listed. Once the human reference sequence for
this region is available from the Human Genome Pro-
ject, it will undoubtedly become easier to identify and
localize genes within the LSFC critical region.
LD has previously been used as a powerful tool for
the high-resolution mapping of disease genes in founder
populations, such as the diastrophic dysplasia gene in
Finland (Hastbacka et al. 1992) and the genes for
pseudo–vitamin D–deficiency rickets and for autosomal
recessive spastic ataxia in the SLSJ region (Richter et
al. 1999). However, these loci had first been identified
by traditional linkage analysis. The current study is one
of the first examples of a disease-gene locus identified
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solely by the use of a whole-genome LD-mapping ap-
proach. This approach has recently been proposed as a
means of using a dense set of SNPs to localize suscep-
tibility genes for common traits. Because the experi-
mental data are insufficient, it is not yet clear whether
this approach is applicable to common alleles in the
general population. In isolated populations, however,
where there has been a narrow bottleneck or where the
frequency of the variant is !5%, the LD is expected to
extend over a greater region (Kruglyak 1999). Taken
together, our results suggest that whole-genome LD
searches would be feasible for other rare traits and may
also be possible for some common diseases in the SLSJ
region.
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